Invention Grant
US08097597B2 Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors
有权
使用低剂量的反义TGF-和bgr的寡核苷酸; 基因治疗脑肿瘤
- Patent Title: Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors
- Patent Title (中): 使用低剂量的反义TGF-和bgr的寡核苷酸; 基因治疗脑肿瘤
-
Application No.: US11792041Application Date: 2006-05-04
-
Publication No.: US08097597B2Publication Date: 2012-01-17
- Inventor: Karl-Hermann Schlingensiepen , Reimar Schlingensiepen
- Applicant: Karl-Hermann Schlingensiepen , Reimar Schlingensiepen
- Applicant Address: DE Regensburg
- Assignee: Antisense Pharma GmbH
- Current Assignee: Antisense Pharma GmbH
- Current Assignee Address: DE Regensburg
- Agency: Morrison & Foerster LLP
- Priority: EP05009802 20050505
- International Application: PCT/EP2006/062067 WO 20060504
- International Announcement: WO2006/117400 WO 20061109
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C07H21/04 ; C07H21/02
Abstract:
This invention is related to the use of at least one oligonucleotide with a length of from about 8 to about 30 nucleotide building blocks for manufacturing a pharmaceutical preparation for the prophylaxis and/or the treatment of diseases, that are modulated by TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos, and/or prostaglandin E2 in a mammal, wherein said oligonucleotide hybridizes with a messenger RNA of a TGF-beta2, TGF-beta1, TGF-beta3, VEGF, interleukin-10, c-jun, c-fos and/or prostaglandin E2 gene and wherein said preparation comprises said oligonucleotide in a concentration of about 1 microM to about 25 microM.
Public/Granted literature
Information query
